🍽️ acitretin,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Retinoid Derivative: Acitretin is a synthetic retinoid derivative of vitamin A (retinol) that modulates cellular differentiation, proliferation, and inflammation in the skin. It exerts its therapeutic effects by binding to nuclear receptors and regulating gene expression involved in keratinocyte differentiation and epidermal turnover.

  2. Treatment of Psoriasis: Acitretin is indicated for the treatment of severe psoriasis, including plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis, which are resistant to or not adequately controlled by other therapies. It helps reduce the severity and extent of psoriatic lesions, alleviate symptoms such as scaling and itching, and improve overall quality of life.

  3. Psoriatic Arthritis: Acitretin may also be used as an adjunctive therapy in the management of psoriatic arthritis, a chronic inflammatory arthritis associated with psoriasis. While acitretin primarily targets cutaneous manifestations of psoriasis, it may provide additional benefits in patients with psoriatic arthritis by reducing skin involvement and inflammation.

  4. Mechanism of Action: The exact mechanism of action of acitretin in psoriasis is not fully understood, but it is thought to involve normalization of abnormal keratinocyte proliferation and differentiation, suppression of inflammatory cytokines, and modulation of immune responses in the skin.

  5. Long-term Therapy: Acitretin is typically used as a long-term therapy for psoriasis, often in combination with other treatments such as topical corticosteroids, phototherapy (UVB or PUVA), or biologic agents. Long-term maintenance therapy with acitretin may help control psoriatic symptoms and prevent disease relapse.

  6. Dosage and Administration: Acitretin is administered orally in the form of capsules. The dosage and duration of treatment depend on the severity of the psoriasis, individual patient response, and tolerability. It is usually initiated at a low dose and titrated gradually to achieve optimal therapeutic effects while minimizing side effects.

  7. Side Effects: Common side effects of acitretin may include dry skin, cheilitis (inflammation of the lips), pruritus (itching), hair loss, and photosensitivity (increased sensitivity to sunlight). Other potential side effects may include mucocutaneous effects (e.g., conjunctivitis, dry eyes), hepatotoxicity (liver damage), hyperlipidemia (elevated lipid levels), and teratogenicity (birth defects).

  8. Contraindications and Precautions: Acitretin is contraindicated in pregnant women or women of childbearing potential due to its teratogenic effects. Female patients of childbearing age must use effective contraception before, during, and for at least three years after discontinuing acitretin therapy. It is also contraindicated in patients with severe hepatic or renal impairment.

  9. Monitoring: Patients receiving acitretin therapy require regular monitoring of liver function tests, lipid levels, and signs of adverse effects such as mucocutaneous symptoms or mood changes. Monitoring is particularly important during long-term treatment to detect and manage potential side effects.

  10. Discontinuation and Withdrawal: Acitretin therapy should be discontinued gradually, and patients should be monitored for potential rebound flare-ups of psoriasis or exacerbation of symptoms upon discontinuation. A washout period may be necessary before starting alternative therapies, especially in patients switching to medications with overlapping toxicities.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of acitretin,(prescription) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Akkermansia muciniphila Reduces
species Bacteroides uniformis Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
species Parabacteroides distasonis Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by acitretin,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Clostridioides genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Blautia genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Mediterraneibacter genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Akkermansia genus Decreases 📓 Source Study
Clostridium perfringens A no rank Decreases 👶 Source Study
Clostridium perfringens D no rank Decreases 👶 Source Study
Escherichia coli O55:H7 no rank Decreases 👶 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
environmental samples no rank Decreases 👶 Source Study
unclassified Akkermansia no rank Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O126:H45 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:NM serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O167:H26 serotype Decreases 👶 Source Study
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O6:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli O78:H4 serotype Decreases 👶 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Clostridioides difficile species Decreases 📓 Source Study Colitis
Agathobacter rectalis species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Mediterraneibacter gnavus species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Streptococcus parasanguinis species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study High Levels linked to long-lived individuals
Bifidobacterium longum species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Akkermansia glycaniphila species Decreases 👶 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study

Impact of acitretin,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.1 -0.1
ADHD 3.3 0.1 32
Age-Related Macular Degeneration and Glaucoma 0.4 0.4 0
Allergic Rhinitis (Hay Fever) 1.9 0.6 2.17
Allergies 3.6 2.2 0.64
Allergy to milk products 1.7 0.8 1.13
Alopecia (Hair Loss) 1.6 1.6
Alzheimer's disease 2.3 4.7 -1.04
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.6 1.2 0.33
Ankylosing spondylitis 3.2 1.2 1.67
Anorexia Nervosa 0.4 2.3 -4.75
Antiphospholipid syndrome (APS) 1.6 1.6
Asthma 0.6 0.9 -0.5
Atherosclerosis 1 2.4 -1.4
Atrial fibrillation 2.3 1.3 0.77
Autism 8.3 6 0.38
Barrett esophagus cancer 0.1 0.2 -1
benign prostatic hyperplasia 0.3 0.3
Biofilm 1.5 1.5
Bipolar Disorder 1.3 1.1 0.18
Brain Trauma 0.5 0.6 -0.2
Cancer (General) 0.3 2.2 -6.33
Carcinoma 2.7 2.2 0.23
Celiac Disease 1.9 2.2 -0.16
Cerebral Palsy 1 1.4 -0.4
Chronic Fatigue Syndrome 5.4 5.2 0.04
Chronic Kidney Disease 2.2 1.8 0.22
Chronic Lyme 0.6 -0.6
Chronic Obstructive Pulmonary Disease (COPD) 1.1 0.5 1.2
Chronic Urticaria (Hives) 1.6 1 0.6
Coagulation / Micro clot triggering bacteria 1.4 1.4 0
Colorectal Cancer 3.6 0.9 3
Constipation 1 0.8 0.25
Coronary artery disease 1.8 0.6 2
COVID-19 7.2 9.8 -0.36
Crohn's Disease 5.3 4.1 0.29
cystic fibrosis 0.9 0.7 0.29
deep vein thrombosis 0.9 1.1 -0.22
Depression 6.3 7.3 -0.16
Dermatomyositis 0.2 0.1 1
Eczema 1 1.6 -0.6
Endometriosis 2.2 0.9 1.44
Eosinophilic Esophagitis 0.1 -0.1
Epilepsy 2.1 2 0.05
Fibromyalgia 2.4 1.4 0.71
Functional constipation / chronic idiopathic constipation 5.1 3.2 0.59
gallstone disease (gsd) 2 0.5 3
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.1 0.9 0.22
Generalized anxiety disorder 1.8 1.1 0.64
giant cell arteritis 0.4 -0.4
Glioblastoma 0.2 -0.2
Gout 0.1 -0.1
Graves' disease 1.1 1.2 -0.09
Halitosis 0.3 0.2 0.5
Hashimoto's thyroiditis 2 0.3 5.67
Hidradenitis Suppurativa 0.2 0.1 1
High Histamine/low DAO 2.3 0.6 2.83
hypercholesterolemia (High Cholesterol) 0.8 0.2 3
hyperglycemia 0.3 1.3 -3.33
Hyperlipidemia (High Blood Fats) 0.6 0.4 0.5
hypersomnia 0.4 -0.4
hypertension (High Blood Pressure 2.1 2.7 -0.29
Hypothyroidism 0.6 -0.6
Hypoxia 0.7 0.7
IgA nephropathy (IgAN) 2.3 -2.3
Inflammatory Bowel Disease 3.4 8 -1.35
Insomnia 0.8 0.6 0.33
Intelligence 0.6 0.4 0.5
Intracranial aneurysms 1.4 0.4 2.5
Irritable Bowel Syndrome 3.2 2.6 0.23
Liver Cirrhosis 3.5 2.2 0.59
Long COVID 5.3 6.1 -0.15
Low bone mineral density 0.5 -0.5
Lung Cancer 0.6 1 -0.67
Mast Cell Issues / mastitis 0.5 0.7 -0.4
ME/CFS with IBS 1.2 1.3 -0.08
ME/CFS without IBS 1.2 1.1 0.09
Menopause 1.2 1.2
Metabolic Syndrome 6.5 4.8 0.35
Mood Disorders 8.6 7.3 0.18
multiple chemical sensitivity [MCS] 0.9 0.4 1.25
Multiple Sclerosis 2.8 5.4 -0.93
Multiple system atrophy (MSA) 0.7 0.9 -0.29
neuropathic pain 0.4 -0.4
Neuropathy (all types) 0.7 0.3 1.33
neuropsychiatric disorders (PANDAS, PANS) 0.9 0.9
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.1 3.8 -0.81
NonCeliac Gluten Sensitivity 1.1 0.3 2.67
Obesity 6.6 3.5 0.89
obsessive-compulsive disorder 5.9 3.5 0.69
Osteoarthritis 1.9 0.5 2.8
Osteoporosis 1.5 0.8 0.88
pancreatic cancer 0.5 0.5
Parkinson's Disease 5.5 5 0.1
Polycystic ovary syndrome 2.6 2.3 0.13
Postural orthostatic tachycardia syndrome 0.4 0.3 0.33
Premenstrual dysphoric disorder 0.9 0.4 1.25
primary biliary cholangitis 0.4 -0.4
Psoriasis 3.6 2.5 0.44
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 4.8 2.5 0.92
Rosacea 1.4 0.8 0.75
Schizophrenia 4.2 1.9 1.21
scoliosis 0.1 0.5 -4
Sjögren syndrome 2.2 1.8 0.22
Sleep Apnea 1.1 1.1 0
Slow gastric motility / Gastroparesis 1.3 0.1 12
Small Intestinal Bacterial Overgrowth (SIBO) 0.8 0.2 3
Stress / posttraumatic stress disorder 2.2 1.4 0.57
Systemic Lupus Erythematosus 2.9 1.6 0.81
Tic Disorder 1.3 0.9 0.44
Tourette syndrome 0.1 0.2 -1
Type 1 Diabetes 3.2 1.9 0.68
Type 2 Diabetes 6.6 4.6 0.43
Ulcerative colitis 2.4 3.9 -0.63
Unhealthy Ageing 4.4 1.9 1.32
Vitiligo 1.2 1.3 -0.08

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [35.170.81 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.170.81 ]